Lupin Gets USFDA Nod for Generic Allergic Conjunctivitis Relief Medication

28 Dec 2023 , 03:29 PM

Lupin Ltd receives approval from the USFDA to market its generic Loteprednol Etabonate ophthalmic suspension for seasonal allergic conjunctivitis relief.

The approval is for the abbreviated new drug application for Loteprednol Etabonate ophthalmic suspension, 0.2%, as a generic equivalent to Alrex ophthalmic suspension, 0.2% by Bausch & Lomb Inc.

Lupin’s Pithampur facility in India will manufacture the approved product. Loteprednol Etabonate ophthalmic suspension, 0.2%, addresses the temporary relief of signs and symptoms of seasonal allergic conjunctivitis.

The product’s estimated annual sales in the US market are USD 29.1 million, according to IQVIA MAT October 2023 data.

For feedback and suggestions, write to us at [e-mail]